Abstract

Dopamine causes inhibition of Na+,K+-ATPase activity via activation of dopamine D1-like receptors. It is the phosphorylation of Serine18 of the α1-subunit of Na+,K+-ATPase which results in the inhibition of the enzyme activity; however, such a phosphorylation by dopamine D1-like receptor agonist has not been demonstrated in the proximal tubules. We show here by immunoprecipitation and detection with phosphoserine antibody that SKF 38393, a dopamine D1-like receptor agonist, causes phosphorylation of the α1-subunit of Na+,K+-ATPase. The effect of (±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride, SKF 38393, is blocked by R(+)-7-choro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzazepine hydrochloride, SCH 23390, a dopamine D1-like receptor antagonist, and staurosporin, a protein kinase C inhibitor. The phosphorylation is also increased by phorbol 12–13 dibutyrate ester. However, Rp-cAMP triethylamine, an inhibitor of protein kinase A, does not affect the SKF 38393-mediated phosphorylation of Na+,K+-ATPase. Therefore, these results provide the evidence that dopamine D1-like receptor activation causes phosphorylation of the α1-subunit of Na+,K+-ATPase in renal proximal tubules via protein kinase C pathway.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.